title: Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) - Lesson from Adjudin.
abstract: The blood-testis barrier (BTB) is one of the tightest blood-tissue barriers in the mammalian body. It divides the seminiferous epithelium of the seminiferous tubule, the functional unit of the testis, where spermatogenesis takes place, into the basal and the adluminal (apical) compartments. Functionally, the BTB provides a unique microenvironment for meiosis I/II and post-meiotic spermatid development which take place exclusively in the apical compartment, away from the host immune system, and it contributes to the immune privilege status of testis. However, the BTB also poses major obstacles in developing male contraceptives (e.g., adjudin) that exert their effects on germ cells in the apical compartment, such as by disrupting spermatid adhesion to the Sertoli cell, causing germ cell exfoliation from the testis. Besides the tight junction (TJ) between adjacent Sertoli cells at the BTB that restricts the entry of contraceptives from the microvessels in the interstitium to the adluminal compartment, drug transporters, such as P-glycoprotein and multidrug resistance-associated protein 1 (MRP1), are also present that actively pump drugs out of the testis, limiting drug bioavailability. Recent advances in drug formulations, such as drug particle micronization (<50 μm) and co-grinding of drug particles with ß-cyclodextrin have improved bioavailability of contraceptives via considerable increase in solubility. Herein, we discuss development in drug formulations using adjudin as an example. We also put emphasis on the possible use of nanotechnology to deliver adjudin to the apical compartment with multidrug magnetic mesoporous silica nanoparticles. These advances in technology will significantly enhance our ability to develop effective non-hormonal male contraceptives for men.
authors.forename: Haiqi
authors.initials: H
authors.lastname: Chen
authors.forename: Dolores D
authors.initials: DD
authors.lastname: Mruk
authors.forename: Weiliang
authors.initials: W
authors.lastname: Xia
authors.forename: Michele
authors.initials: M
authors.lastname: Bonanomi
authors.forename: Bruno
authors.initials: B
authors.lastname: Silvestrini
authors.affiliation: Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave, New York 10065, USA.. YCheng@popcbr.rockefeller.edu.
authors.forename: Chuen-Yan
authors.initials: CY
authors.lastname: Cheng
mesh_terms: D000818:Animals; D001814:Blood-Testis Barrier / Q000378:metabolism*; D003272:Contraceptive Agents, Male / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D007191:Indazoles / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D008297:Male; D036103:Nanotechnology
chemical_list: C432482:1-(2,4-dichlorobenzyl)indazole-3-carbohydrazide; D003272:Contraceptive Agents, Male; D006834:Hydrazines; D007191:Indazoles